scholarly journals EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3‐YEAR FOLLOW‐UP

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
A Janssens ◽  
S Snauwaert ◽  
D Bron ◽  
Z Berneman ◽  
F Offner ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Routine Clinical Practice ◽  
Lymphocytic Leukemia ◽  
Mantle Cell

scholarly journals Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014 ◽  
Vol 25 ◽  
pp. iii83-iii92 ◽  
Author(s):  
M. Dreyling ◽  
C. Geisler ◽  
O. Hermine ◽  
H.C. Kluin-Nelemans ◽  
S. Le Gouill ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Mantle Cell Lymphoma ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cell Lymphoma ◽  
Newly Diagnosed ◽  
Mantle Cell

scholarly journals Mantle cell lymphoma and chronic lymphocytic leukemia: report of a rare disease association and review of the literature

2010 ◽  
Vol 3 (2-3) ◽  
pp. 91-99 ◽  
Author(s):  
Joana Perdigão ◽  
Helena Alaiz ◽  
Paulo Lúcio ◽  
Paula Gameiro ◽  
Marta Sebastião ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Mantle Cell Lymphoma ◽  
Rare Disease ◽  
Cell Lymphoma ◽  
Disease Association ◽  
Lymphocytic Leukemia ◽  
Review Of The Literature ◽  
Mantle Cell

scholarly journals Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions

Blood ◽  
2018 ◽  
Vol 131 (21) ◽  
pp. 2283-2296 ◽  
Author(s):  
Xose S. Puente ◽  
Pedro Jares ◽  
Elias Campo
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Variable Region ◽  
Lymphocytic Leukemia ◽  
Variable Load ◽  
Genomic Alterations ◽  
Clinical Evolution ◽  
Mantle Cell ◽  
Epidemiological Characteristics

Abstract Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are 2 well-defined entities that diverge in their basic pathogenic mechanisms and clinical evolution but they share epidemiological characteristics, cells of origin, molecular alterations, and clinical features that differ from other lymphoid neoplasms. CLL and MCL are classically considered indolent and aggressive neoplasms, respectively. However, the clinical evolution of both tumors is very heterogeneous, with subsets of patients having stable disease for a long time whereas others require immediate intervention. Both CLL and MCL include 2 major molecular subtypes that seem to derive from antigen-experienced CD5+ B cells that retain a naive or memory-like epigenetic signature and carry a variable load of immunoglobulin heavy-chain variable region somatic mutations from truly unmutated to highly mutated, respectively. These 2 subtypes of tumors differ in their molecular pathways, genomic alterations, and clinical behavior, being more aggressive in naive-like than memory-like–derived tumors in both CLL and MCL. The pathogenesis of the 2 entities integrates the relevant influence of B-cell receptor signaling, tumor cell microenvironment interactions, genomic alterations, and epigenome modifications that configure the evolution of the tumors and offer new possibilities for therapeutic intervention. This review will focus on the similarities and differences of these 2 tumors based on recent studies that are enhancing the understanding of their pathogenesis and creating solid bases for new management strategies.

CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma

2010 ◽  
Vol 34 (9) ◽  
pp. 1235-1238 ◽  
Author(s):  
Dragan Jevremovic ◽  
Roxana S. Dronca ◽  
William G. Morice ◽  
Ellen D. McPhail ◽  
Paul J. Kurtin ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Lymphoproliferative Disorders ◽  
Lymphocytic Leukemia ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document